Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+4.43%
$19.76
100% positive prob.
5-Day Prediction
+9.38%
$20.69
100% positive prob.
20-Day Prediction
+5.20%
$19.90
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q4 2025 | BUY | +4.43% | +9.38% | +5.20% | 100.0% | Pending |
| Q3 2025 | BUY | +4.27% | +10.25% | +5.19% | 100.0% | +2.38% |
SEC 8-K filings with transcript text
Mar 3, 2026 · 100% conf.
1D
+4.43%
$19.76
Act: +1.59%
5D
+9.38%
$20.69
20D
+5.20%
$19.90
8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 3, 2026
STAAR Surgical Company (Exact Name of Registrant as Specified in Charter)
Delaware
0-11634
95-3797439
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
25510 Commercentre Drive Lake Forest, California
92630
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 626-303-7902 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 3, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter and year ended January 2, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
Item 7.01 Regulation FD Disclosure.
During a conference call and webcast scheduled to be held at 5:30 p.m. Eastern / 2:30 p.m. Pacific on March 3, 2026, the Company’s Interim Co-Chief Executive Officer, President and Chief Operating Officer and the Company's Interim Co-Chief Executive officer and Chief Financial Officer will discuss the Company’s results for the quarter and year ended January 2, 2026. The Company’s shareholder letter for the conference call is furnished as Exhibit 99.2 to this Current Report.
The information furnished herewith pursuant to Items 2.02 and 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Items 2.02 and 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press release of the Company dated March 3, 2026.
99.2
Shareholder letter of the Company dated March 3, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company
March 3, 2026
By:
/s/ DEBORAH ANDREWS
Deborah Andrews
Interim Co-Chief Executive Officer and
Chief Financial Officer
Nov 5, 2025 · 100% conf.
1D
+4.27%
$26.33
Act: +5.66%
5D
+10.25%
$27.84
Act: +2.38%
20D
+5.19%
$26.56
Act: +5.35%
8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 5, 2025
STAAR Surgical Company (Exact Name of Registrant as Specified in Charter)
Delaware
0-11634
95-3797439
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
25510 Commercentre Drive Lake Forest, California
92630
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 626-303-7902 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2025, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended September 26, 2025, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information furnished herewith pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press release of the Company dated November 5, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company
November 5, 2025
By:
/s/ Stephen C. Farrell
Stephen C. Farrell
Chief Executive Officer
Oct 20, 2025 · 100% conf.
1D
+4.27%
$26.33
Act: +5.66%
5D
+10.25%
$27.84
Act: +2.38%
20D
+5.19%
$26.56
Act: +5.35%
8-K
STAAR SURGICAL CO false 0000718937 0000718937 2025-10-20 2025-10-20
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025
STAAR Surgical Company (Exact name of registrant as specified in its charter)
Delaware
0-11634
95-3797439
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
25510 Commercentre Drive
Lake Forest, California
92630
(Address of principal executive offices)
(Zip Code) 626-303-7902 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 20, 2025, STAAR Surgical Company (the “Company”) published a press release reporting its preliminary net sales results for the quarter ended September 26, 2025, a copy of which is filed as Exhibit 99.1 to this report and is incorporated herein by this reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit Number
Exhibit
99.1
Press release of the Company dated October 20, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company
Date: October 20, 2025
By:
/s/ Stephen C. Farrell
Name:
Stephen C. Farrell
Title:
Chief Executive Officer
This page provides STAAR Surgical Company (STAA) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on STAA's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.